These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 39412631

  • 1. Real-World Safety and Effectiveness of Infliximab in 255 Patients with Intestinal, Neurological, and Vascular Behçet's Disease: A Post-Marketing Surveillance.
    Hibi T, Hirohata S, Hisamatsu T, Kikuchi H, Takeno M, Sato N, Mizuno N, Tashiro M, Susuta Y, Ishigatsubo Y.
    Adv Ther; 2024 Dec; 41(12):4476-4497. PubMed ID: 39412631
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet's disease: a large-scale, long-term postmarketing surveillance in Japan.
    Ohno S, Umebayashi I, Matsukawa M, Goto T, Yano T.
    Arthritis Res Ther; 2019 Jan 05; 21(1):2. PubMed ID: 30611312
    [Abstract] [Full Text] [Related]

  • 3. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study.
    Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K, Kondo K, Ishigatsubo Y.
    Medicine (Baltimore); 2016 Jun 05; 95(24):e3863. PubMed ID: 27310969
    [Abstract] [Full Text] [Related]

  • 4. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
    Sugimura N, Mizoshita T, Sugiyama T, Togawa S, Miyaki T, Suzuki T, Tanida S, Kataoka H, Sasaki M.
    Dig Liver Dis; 2019 Jul 05; 51(7):967-971. PubMed ID: 30872086
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness and safety of adalimumab in patients with intestinal Behçet's disease: a real-world prospective observational study in South Korea.
    Yu J, Shin SJ, Park YJ, Kim HW, Lee BI, Ye BD, Kim GT, Kim SK, Kim JS, Kim YH, Jeong S, Cheon JH.
    BMC Gastroenterol; 2023 Dec 19; 23(1):449. PubMed ID: 38114956
    [Abstract] [Full Text] [Related]

  • 6. Characteristics of neurological manifestations of Behçet's disease: a retrospective monocentric study in Tunisia.
    Houman MH, Bellakhal S, Ben Salem T, Hamzaoui A, Braham A, Lamloum M, Monia SK, Ben Ghorbel I.
    Clin Neurol Neurosurg; 2013 Oct 19; 115(10):2015-8. PubMed ID: 23830180
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and Safety of Infliximab in Intestinal Behçet's Disease: A Multicenter, Phase 3 Study (BEGIN).
    Cheon JH, Kim HS, Han DS, Kim SK, Shin SJ, Kim JS, Ye BD, Song GA, Lee Y, Kim Y, Lee Y, Kim WH, BEGIN Study Group.
    Gut Liver; 2023 Sep 15; 17(5):777-785. PubMed ID: 36578194
    [Abstract] [Full Text] [Related]

  • 8. Clinical features and disease course of neurological involvement in Behcet's disease: HUVAC experience.
    Bolek EC, Sari A, Kilic L, Kalyoncu U, Kurne A, Oguz KK, Topcuoglu MA, Ertenli I, Karadag O.
    Mult Scler Relat Disord; 2020 Feb 15; 38():101512. PubMed ID: 31733425
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy of TNFα inhibitors for refractory vascular Behçet's disease: A multicenter observational study of 27 patients and a review of the literature.
    Aksoy A, Yazici A, Omma A, Cefle A, Onen F, Tasdemir U, Ergun T, Direskeneli H, Alibaz-Oner F.
    Int J Rheum Dis; 2020 Feb 15; 23(2):256-261. PubMed ID: 31976619
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
    Park J, Cheon JH.
    Gut Liver; 2018 Nov 15; 12(6):623-632. PubMed ID: 29788675
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mucosal Healing at 14 Weeks Predicts better Outcome in Low-dose Infliximab Treatment for Chinese Patients with Active Intestinal Behcet's Disease.
    Zou J, Ji DN, Shen Y, Guan JL, Zheng SB.
    Ann Clin Lab Sci; 2017 Mar 15; 47(2):171-177. PubMed ID: 28442519
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic approach to central nervous system involvement of Behçet's disease.
    Sota J, Capuano A, Emmi G, Iannone F, Cantarini L, Hatemi G, Lopalco G.
    Semin Arthritis Rheum; 2023 Aug 15; 61():152206. PubMed ID: 37172497
    [Abstract] [Full Text] [Related]

  • 17. Behçet's disease; A rare refractory patient with vena cava superior syndrome treated with infliximab: a case report and review of the literature.
    Uyaroglu OA, Erden A, Kilic L, Peynircioğlu B, Karadag O, Kalyoncu U.
    Acta Clin Belg; 2019 Oct 15; 74(5):364-369. PubMed ID: 30220250
    [Abstract] [Full Text] [Related]

  • 18. Management of severe complications in Behçet's disease with TNF inhibitors.
    Desbois AC, Vallet H, Domont F, Comarmond C, Cacoub P, Saadoun D.
    Expert Opin Biol Ther; 2017 Jul 15; 17(7):853-859. PubMed ID: 28503960
    [Abstract] [Full Text] [Related]

  • 19. Infliximab versus Cyclophosphamide for Severe Behçet's Syndrome.
    Saadoun D, Maalouf G, Vieira M, Trad S, Lazaro E, Sacre K, Plessier A, Sené T, Koné-Paut I, Noel N, Mekinian A, Lambert M, Ribeiro E, Mirault T, Mele N, Dellal A, Fain O, Melki I, Chiche L, Gaudric J, Redheuil A, Maillart E, Ghembaza A, Desbois AC, Mirouse A, Domont F, Leroux G, Ferfar Y, Rigolet A, Viallard JF, Vautier M, Resche-Rigon M, Cacoub P.
    NEJM Evid; 2024 Nov 15; 3(11):EVIDoa2300354. PubMed ID: 39437137
    [Abstract] [Full Text] [Related]

  • 20. Neuro-behçet's disease in South Korea: clinical characteristics and treatment response.
    Yoon DL, Kim YJ, Koo BS, Kim YG, Lee CK, Yoo B.
    Int J Rheum Dis; 2014 May 15; 17(4):453-8. PubMed ID: 24506839
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.